RTP Mobile Logo
Rounds with the Investigators: National Research Leaders Provide Their Perspectives on the Management of Actual Patients with Multiple Myeloma
Released July 2012

A case–based roundtable discussion featuring interviews with Drs Rafael Fonseca, Ravi Vij, Jeffrey L Wolf and Jeffrey A Zonder. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancers and carries with it the worst death to new cases ratio (3:4) among all the blood cancer subtypes. Patients with smoldering (asymptomatic) myeloma may be cared for by observation only because the course of disease is often indolent for many years without therapy. However, patients with more advanced, active disease require immediate induction therapy in an effort to prepare eligible candidates for autologous stem cell transplant (ASCT). Optimal initial induction therapy for both ASCT candidates and those not eligible remains an area of clinical controversy, and multiple acceptable treatment options appear to merit consideration. Recent clinical research demonstrates an abundance of treatment options now available to patients with both newly diagnosed and relapsed or refractory MM.

    To provide clinicians with therapeutic strategies to address the disparate needs of patients with MM, the Rounds with the Investigators audio series employs an innovative case-based approach that gathers the perspectives of leading MM investigators and community oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, medical oncologists and hematologists should be able to formulate an up-to-date and more complete approach to the care of patients with MM.

    LEARNING OBJECTIVES

    • Employ case-based learning to effectively implement evidence-based diagnostic and therapeutic approaches for patients with newly diagnosed and relapsed/refractory MM.
    • Recognize and apply essential patient care considerations that enable the successful delivery of proteasome inhibitor- and/or IMiD-containing systemic therapy for MM.
    • Adhere to published guidelines and expert recommendations when selecting frequency of administration and total duration of bisphosphonates for patients with MM.
    • Appropriately identify and counsel patients with MM who may experience quantitative and qualitative benefit from stem cell transplantation.
    • Recognize treatment-associated side effects and offer patients acceptable alternative dosing/administration and/or supportive management interventions to address them.
    • Use biomarkers to assess risk for patients with MM, and recommend systemic treatment commensurate with prognosis and likelihood of therapeutic response in the induction, consolidation and maintenance settings.
    • Recall emerging efficacy and safety data with newer-generation IMiDs and proteasome inhibitors currently under investigation in MM.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY


    This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CDs, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/RWIMM112/CME.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FonsecaConsulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Intellikine, Lilly USA LLC, Medtronic Inc, Millennium: The Takeda Oncology Company, Otsuka Pharmaceutical Co Ltd; Research Support: Celgene Corporation, Cylene Pharmaceuticals, Onyx Pharmaceuticals Inc. Dr VijAdvisory Committee: Eisai Inc, Onyx Pharmaceuticals Inc; Consulting Agreements: Abbott Laboratories, Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Cephalon Inc, Millennium: The Takeda Oncology Company. Dr WolfConsulting Agreement: Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. Dr ZonderConsulting Agreement: Amgen Inc; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

    COMMUNITY PANELDrs Hager, Joshua and Lobins had no real or apparent conflicts of interest to disclose. Dr BrennerSpeakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company; Stock Ownership: Celgene Corporation. Dr FarberAdvisory Committee: Genentech BioOncology, Millennium: The Takeda Oncology Company; Speakers Bureau: Alexion Pharmaceuticals, Celgene Corporation, Genentech BioOncology; Stock Ownership: Alexion Pharmaceuticals.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Millennium: The Takeda Oncology Company and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio


    Last review date: July 2012
    Expiration date: July 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Rounds with the Investigators: National Research Leaders Provide Their Perspectives on the Management of Actual Patients with Multiple Myeloma
Released July 2012

A case–based roundtable discussion featuring interviews with Drs Rafael Fonseca, Ravi Vij, Jeffrey L Wolf and Jeffrey A Zonder. (Audio Content)

Read print: